Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soursop Tea in Relapsed/Refractory AML or MM
NCT07771803Phase 1Recruiting
- Sponsor
- Aileron Therapeutics
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute myeloid leukemia (AML) and multiple myeloma (MM) (2 arms), sponsored by Aileron Therapeutics. Primary endpoints: Safety and Toxicity at 21 days and Reduction in Malignant Cell Burden at 21 days. Started Jun 2025; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07771803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07771803.